Bulk procurement agreements between the Ministry of Health and CGMS manufacturers could be leveraged in device price negotiations, while collaborating with insurers to include CGMS as a reimbursable device within healthcare benefits could further alleviate financial burdens, particularly for insulin-requiring T1DM patients. Here, INS is linked to type 1 diabetes mellitus.